The market for Minimal Residual Disease (MRD) Testing is expected to grow rapidly, reaching an estimated value of $2,858.1 million by 2031 and registering a strong CAGR of 12.4% from 2021 to 2031. The market is growing as a result of the ageing population and rising rates of cancer and haematological malignancies. The market’s consistent growth is also greatly influenced by substantial investments in research & development, which result in technological improvements in medicines and diagnostics as well as rising healthcare costs.
Leukaemia and lymphoma are two haematological cancers that have increased recently, creating a major healthcare burden on a global scale. The demand for precise and sensitive diagnostic procedures, such as minimal residual disease (MRD) testing, is rising as these diseases become more common. MRD testing gives medical professionals the ability to find and keep track of any cancer cells that remain after therapy, which helps them evaluate the efficacy of medications and decide on the best course of action. The market for MRD testing is expanding as a result of the growing need for precise cancer diagnosis.
Get Full PDF Sample Copy of Report: https://marketdatalibrary.com/download-sample/4066
The subject of diagnosing and treating haematological cancers has undergone a major transformation because to technological developments. Growing investments in R&D have led to the creation of sophisticated molecular and genetic testing methods, improving the precision and dependability of MRD testing. Additionally, the efficiency and precision of MRD testing have been greatly increased by the integration of next-generation sequencing, flow cytometry, and polymerase chain reaction technologies, thus boosting market growth.
The increasing incidence of cancer and haematological malignancies, technological advances in diagnostics and treatments, and rising healthcare costs are all likely to contribute to the significant growth of the global minimal residual disease (MRD) testing market. Businesses operating in this market can take advantage of the rising need for precise cancer diagnostics to capitalise on the market’s predicted valuation of $2,800 million or more by 2031 to achieve significant growth.
Highlighted with 86 tables and 87 figures, this 170-page report “Global Minimal Residual Disease (MRD) Testing Market 2021-2031 by Offering (Services, Test Kits & Consumables), Application (NHL, MM, ALL, CLL, AML, CML, HL, Solid Tumor), Technology (Flow Cytometry, PCR, NGS, Others), End User (Hospitals and Clinics, Research Institutions, Diagnostic Laboratories, Others), and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global minimal residual disease (MRD) testing market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
- Market Structure
- Growth Drivers
- Restraints and Challenges
- Emerging Product Trends & Market Opportunities
- Porter’s Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify global minimal residual disease (MRD) testing market in every aspect of the classification from perspectives of Offering, Application, Technology, End User, and Region.
View Report Scope and Latest Developments in the Market: MW Link https://www.marketwatch.com/press-release/minimal-residual-disease-mrd-testing-market-revenue-growth-to-stoke-up-in-next-couple-of-years-key-players-profile-outlook-and-forecast-till-2032-2023-06-04?mod=search_headline
Based on Offering, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
- Services
- Test Kits & Consumables
Based on Application, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
- Non-Hodgkin’s Lymphoma (NHL)
o DLBCL
o Marginal Zone Lymphoma
o Follicular Lymphoma
o Peripheral T-cell Lymphoma
o Mantle Cell Lymphoma
o Other NHLs
- Multiple Myeloma (MM)
- Acute Lymphoblastic Leukemia (ALL)
- Chronic Lymphoblastic Leukemia (CLL)
- Acute Myeloid Leukemia (AML)
- Chronic Myeloid Leukemia (CML)
- Hodgkin’s Lymphoma (HL)
- Solid Tumor
- Other Applications
By Technology, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
- Flow Cytometry
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Other Technologies
By End User, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
- Hospitals and Clinics
- Research Institutions
- Diagnostic Laboratories
- Other End Users
Geographically, the following regions together with the listed national/local markets are fully investigated:
- North America (U.S., Canada, and Mexico)
- Europe (Germany, UK, France, Spain, Italy, Netherlands, Rest of Europe; Rest of Europe is further segmented into Russia, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
- APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
- South America (Brazil, Chile, Argentina, Rest of South America)
- MEA (UAE, Saudi Arabia, South Africa, Other Nations)
For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of all regional markets by country and split of national markets by Application, Technology, and End User over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
- Adaptive Biotechnologies Corporation
- ArcherDX, Inc. (Invitae Corporation)
- Arup Laboratories
- Asuragen Inc.
- Bio-Rad Laboratories, Inc.
- Cergentis B.V.
- Guardant Health
- ICON plc
- Inivata Ltd.
- Invivoscribe, Inc.
- Laboratory Corporation of America Holdings
- Mission Bio, Inc.
- Natera, Inc.
- NeoGenomics Laboratories, Inc.
- Opko Health, Inc.
- Quest Diagnostics Incorporated
- Sysmex Corporation
View Complete TOC and Figures & Graphs of Minimal Residual Disease (MRD) Testing Industry Report https://marketdatalibrary.com/free-customization/4066
About Market Data Library:
Market Data Library is committed to providing clients with high-quality market research that is tailored to their specific needs. The Market Data Library provides corporate intelligence studies that ensure reliable and accurate research data across a diverse range of industries, including Health Care, Chemicals, Packaging, ICT, Automotive, Industrial Automation, Agriculture, and Finance. Our team is comprised of various departments, including sales, operations, finance, research, and analytics, as well as the scientist and data scientist teams. Our business offerings portray the most up-to-date, rational information a company needs to compete effectively. To guarantee that our clients have access to information and insights whenever they need them, we provide 24/7 research support.
Contact Us
Market Data Library
Tel: +1-(718)-312-8686
Email: sales@marketdatalibrary.com
Website: marketdatalibrary.com/
Visit Our Trending Report